Cargando…

Expression of immune check point gene TIM-3 in patients newly diagnosed with acute myeloid leukemia: Significance and impact on outcome

Despite recent advancements in the therapeutic landscape of acute myeloid leukemia (AML), the prognosis of patients remains poor. Immune check point inhibitors have been investigated in hematological malignancies, including AML; however, the role of T-cell immunoglobulin and mucin domain 3 (TIM-3) i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kamal, Amany M., Nabih, Nermeen A., Elleboudy, Nooran S., Radwan, Sara M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933755/ https://www.ncbi.nlm.nih.gov/pubmed/33692857 http://dx.doi.org/10.3892/ol.2021.12587

Ejemplares similares

Check(point) or checkmate for acute myeloid leukemia?
por: Niyongere, Sandrine, et al.
Publicado: (2021)

Invasive Fungal Disease in Patients with Newly Diagnosed Acute Myeloid Leukemia
por: Wasylyshyn, Anastasia I., et al.
Publicado: (2021)

PB1842: EARLY DEATH IN NEWLY DIAGNOSED ADULT ACUTE MYELOID LEUKEMIA
por: Siala, N., et al.
Publicado: (2022)

The prognostic impact of lymphocyte subsets in newly diagnosed acute myeloid leukemia
por: Park, Yumi, et al.
Publicado: (2018)

Upregulation of Tim‐3 is associated with poor prognosis in acute myeloid leukemia
por: Wu, Zhengwei, et al.
Publicado: (2022)

Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia
por: Togasaki, E, et al.
Publicado: (2017)

Upregulation of necroptosis markers RIPK3/MLKL and their crosstalk with autophagy-related protein Beclin-1 in primary immune thrombocytopenia
por: Kamal, Amany M., et al.
Publicado: (2022)

Outcomes of decitabine treatment for newly diagnosed acute myeloid leukemia in older adults
por: Yoo, Kwai Han, et al.
Publicado: (2020)

The risk of early mortality in elderly patients with newly diagnosed acute myeloid leukemia
por: Liu, Chia‐Jen, et al.
Publicado: (2020)

TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
por: Niparuck, Pimjai, et al.
Publicado: (2021)

One Stone, Two Birds: The Roles of Tim-3 in Acute Myeloid Leukemia
por: Wang, Zhiding, et al.
Publicado: (2021)

Evaluating the clinical significance of FLT3 mutation status in Syrian newly diagnosed acute myeloid leukemia patients with normal karyotype
por: Moualla, Yahia, et al.
Publicado: (2022)

Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia
por: Cherry, Evan M., et al.
Publicado: (2021)

The immune receptor Tim-3 acts as a trafficker in a Tim-3/galectin-9 autocrine loop in human myeloid leukemia cells
por: Gonçalves Silva, Isabel, et al.
Publicado: (2016)

Profile of sapacitabine: potential for the treatment of newly diagnosed acute myeloid leukemia in elderly patients
por: Lim, Ming Y, et al.
Publicado: (2014)

Opioid utilization among pediatric patients treated for newly diagnosed acute myeloid leukemia
por: Getz, Kelly D., et al.
Publicado: (2018)

Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients
por: Garciaz, Sylvain, et al.
Publicado: (2022)

Combination of cyclophosphamide and cytarabine as induction regimen for newly diagnosed adult acute myeloid leukemia
por: Liu, Qingguo, et al.
Publicado: (2020)

Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
por: Fleischmann, Maximilian, et al.
Publicado: (2022)

Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia
por: Jonas, Brian A., et al.
Publicado: (2022)

Profile of Glasdegib for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML): Evidence to Date
por: Iyer, Sunil Girish, et al.
Publicado: (2022)

Optimizing Treatment Options for Newly Diagnosed Acute Myeloid Leukemia in Older Patients with Comorbidities
por: Oshikawa, Gaku, et al.
Publicado: (2023)

PD-1 blockade upregulate TIM-3 expression as a compensatory regulation of immune check point receptors in HNSCC TIL
por: Shayan, Gulidanna, et al.
Publicado: (2015)

Multidrug Resistant Acinetobacter baumannii Biofilms: Evaluation of Phenotypic–Genotypic Association and Susceptibility to Cinnamic and Gallic Acids
por: Sherif, Mahmoud M., et al.
Publicado: (2021)

Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
por: DiNardo, Courtney D., et al.
Publicado: (2021)

Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia
por: Roboz, Gail J., et al.
Publicado: (2018)

Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia
por: Park, Hyunsung, et al.
Publicado: (2017)

Timing Embryo Preservation for a Patient with High-Risk Newly Diagnosed Acute Myeloid Leukemia
por: Ye, Rebecca, et al.
Publicado: (2018)

Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy
por: Richard-Carpentier, Guillaume, et al.
Publicado: (2019)

Intensive Chemotherapy in Patients Aged 70 Years or Older Newly Diagnosed With Acute Myeloid Leukemia
por: Ross, Kelly, et al.
Publicado: (2015)

Pulmonary function testing for fitness assessment in asymptomatic adults with newly diagnosed acute myeloid leukemia
por: Palmieri, Raffaele, et al.
Publicado: (2022)

Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia
por: Irani, Yazad D., et al.
Publicado: (2023)

Newly Diagnosed Acute Promyelocytic Leukemia
por: Avvisati, Giuseppe
Publicado: (2011)

SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemia
por: Marrero, Richard J., et al.
Publicado: (2023)

Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis
por: Radich, Jerald P., et al.
Publicado: (2023)

Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia
por: Altman, Jessica K., et al.
Publicado: (2017)

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
por: Cortes, Jorge E., et al.
Publicado: (2018)

First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysis
por: Chen, Kang-Kang, et al.
Publicado: (2018)

An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure
por: Lin, Swan, et al.
Publicado: (2020)

Newly Diagnosed Acute Myeloid Leukemia in a Patient With Severe SARS-CoV-2 Infection
por: Papamichalis, Panagiotis, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hqqdj7ts4ut4ierucu9dn81fuq